KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Shares Issued (2016 - 2025)

NovoCure's Shares Issued history spans 12 years, with the latest figure at $77000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 89.34% year-over-year to $77000.0; the TTM value through Dec 2025 reached $6.1 million, up 197.32%, while the annual FY2025 figure was $6.1 million, 183.53% up from the prior year.
  • Shares Issued for Q4 2025 was $77000.0 at NovoCure, down from $5.8 million in the prior quarter.
  • Across five years, Shares Issued topped out at $8.7 million in Q2 2021 and bottomed at -$15.2 million in Q4 2021.
  • The 5-year median for Shares Issued is $1.6 million (2022), against an average of $2.1 million.
  • The largest annual shift saw Shares Issued tumbled 241.37% in 2021 before it skyrocketed 9136.96% in 2023.
  • A 5-year view of Shares Issued shows it stood at -$15.2 million in 2021, then surged by 100.61% to $92000.0 in 2022, then surged by 9136.96% to $8.5 million in 2023, then plummeted by 91.5% to $722000.0 in 2024, then tumbled by 89.34% to $77000.0 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Shares Issued are $77000.0 (Q4 2025), $5.8 million (Q3 2025), and $251000.0 (Q2 2025).